Oral fingolimod (FTY720) in relapsing multiple sclerosis: Impact on health-related quality of life in a phase II study

Multiple Sclerosis Journal

Volumn 17, Issue 11, 2011, Pages 1341-1350

  Montalban, X ^a   Comi, G ^b   OConnor, P ^c   Gold, S M ^d   De Vera, A ^e   Eckert, B ^e   Kappos, L ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

BDI II; depression; fingolimod; FTY720; HAQUAMS; HRQoL

Indexed keywords

FINGOLIMOD;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 80655149494     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511411061     Document Type: Article

References (44)

1. Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS Drugs. 2008 ; 22: 827-839
2. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients dont agree: cross sectional study of patients and doctors perceptions and assessments of disability in multiple sclerosis. BMJ. 1997 ; 314: 1580-1583
3. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler. 2003 ; 9: 63-72
4. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology. 2000 ; 55: 51-54
5. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005 ; 11: 328-337
6. Dalton EJ, Heinrichs RW. Depression in multiple sclerosis: a quantitative review of the evidence. Neuropsychology. 2005 ; 19: 152-158
7. Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc. 2008 ; 14: 691-724
8. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991 ; 41: 685-691
9. Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci. 2007 ; 14: 919-927
10. Simone IL, Ceccarelli A, Tortorella C, Bellacosa A, Pellegrini F, Plasmati I, et al. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes. 2006 ; 4: 96
11. Isaksson AK, Ahlstrom G, Gunnarsson LG. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 ; 76: 64-69
12. Gold SM, Heesen C, Schulz H, Guder U, Monch A, Gbadamosi J, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler. 2001 ; 7: 119-130
13. Kappos L, Antel J, Comi G, Montalban X, OConnor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 ; 355: 1124-1140
14. OConnor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, et al. Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology. 2009 ; 72: 73-79
15. Montalban X, OConnor P, Antel J, Comi G, Radue EW, de Vera A, et al. Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: 4-year results from a phase II extension. Neurology. 2009 ; 72 (Suppl. 3). A313
16. Pollmann W, Busch C, Voltz R. [Quality of life in multiple sclerosis. Measures, relevance, problems, and perspectives]. Nervenarzt. 2005 ; 76: 154-169
17. Schulz KH, Gold SM, Witte J, Bartsch K, Lang UE, Hellweg R, et al. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci. 2004 ; 225: 11-18
18. Gold SM, Schulz H, Monch A, Schulz KH, Heesen C. Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler. 2003 ; 9: 404-410
19. Gold SM, Schulz H, Stein H, Solf K, Schulz KH, Heesen C. Responsiveness of patient-based and external rating scales in multiple sclerosis: Head-to-head comparison in three clinical settings. J Neurol Sci. 2010 ; 290: 102-106
20. Beck AT, Steer RA, Brown GK Manual for the Beck Depression Inventory second edition (BDI-II). The Psychological Corporation ; 1996 :
21. Storch EA, Roberti JW, Roth DA. Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second Edition in a sample of college students. Depress Anxiety. 2004 ; 19: 187-189
22. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
23. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
24. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
25. Kappos L, Radue EW, OConnor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
26. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?. J Neurol Neurosurg Psychiatry. 2006 ; 77: 34-39
27. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol. 1988 ; 45: 435-437
28. Penner IK, Bechtel N, Raselli C, Stocklin M, Opwis K, Kappos L, et al. Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control. Mult Scler. 2007 ; 13: 1161-1167
29. Krupp LB. Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs. 2003 ; 17: 225-234
30. Merkelbach S, Sittinger H, Koenig J. Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis?. J Nerv Ment Dis. 2002 ; 190: 388-393
31. Janssens AC, van Doorn PA, de Boer JB, van der Meche FG, Passchier J, Hintzen RQ. Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners. Acta Neurol Scand. 2003 ; 108: 389-395
32. Merlino G, Fratticci L, Lenchig C, Valente M, Cargnelutti D, Picello M, et al. Prevalence of poor sleep among patients with multiple sclerosis: An independent predictor of mental and physical status. Sleep Med. 2008 ; 10: 26-34
33. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001 ; 7: 340-344
34. Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H. Fatigue in multiple sclerosis is related to disability, depression and quality of life. J Neurol Sci. 2006 ; 243: 39-45
35. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosch G, Kollegger H, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand. 2004 ; 110: 6-13
36. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005 ; 231: 29-34
37. Benito-Leon J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol. 2002 ; 9: 497-502
38. Kappos L, Comi G, Montalban X, Antel J, de Vera A, Pohlmann H, et al. Oral FTY720 (fingolimod) in relapsing multiple sclerosis: impact on patient-reported depression, as measured by the Beck Depression Inventory II in a 6-month, placebo-controlled study. Neurology. 2007 ; 68: A276
39. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009 ; 29: 309-320
40. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002 ; 159: 1862-1868
41. Haase CG, Tinnefeld M, Lienemann M, Ganz RE, Faustmann PM. Depression and cognitive impairment in disability-free early multiple sclerosis. Behav Neurol. 2003 ; 14: 39-45
42. Putzki N, Katsarava Z, Vago S, Diener HC, Limmroth V. Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients. Eur Neurol. 2008 ; 59: 136-142
43. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract. 2007 ; 61: 1922-1930
44. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006 ; 38: 167-171